Organon & (US:OGN) Prnewswireยท2025-06-04 15:10Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Organon & Co. due to misleading statements regarding its capital allocation strategy, particularly concerning dividends and debt reduction, which led to significant stock price declines for investors [2][4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $75,000 in Organon between October 31, 2024, and April 30, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Organon, with a deadline of July 22, 2025, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Misleading Statements and Financial Impact - Defendants provided materially misleading information about Organon's capital allocation strategy, emphasizing dividends while concealing the prioritization of debt reduction, particularly after the acquisition of Dermavant [4]. - Following the revelation of these misleading statements, Organon's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in one day [5].